The Patent Finder

2'-Substituted-N6-SUBSTITUTED Purine Nucleotides for RNA Virus Treatment

Atea Pharmaceuticals, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application PCT/US2017/050323, filed Sep 6, 2017. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 10,946,0332'-Substituted-N6-SUBSTITUTED Purine Nucleotides for RNA Virus Treatment
In force
 · Medium confidence
Atea Pharmaceuticals, Inc.In force
Medium confidence
US 11,975,0162'-Substituted-N6-SUBSTITUTED Purine Nucleotides for RNA Virus Treatment
In force
 · Low confidence
Atea Pharmaceuticals, Inc.In force
Low confidence
Application 16/821,8502'-Substituted-N6-SUBSTITUTED Purine Nucleotides for RNA Virus Treatment
Abandoned
Abandoned Nov 24, 2021
Atea Pharmaceuticals, Inc.AbandonedAbandoned Nov 24, 2021
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Atea Pharmaceuticals, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited